{"id":8223,"date":"2024-08-11T20:24:29","date_gmt":"2024-08-11T20:24:29","guid":{"rendered":"https:\/\/longchangextracts.com\/?p=8223"},"modified":"2024-08-11T20:24:29","modified_gmt":"2024-08-11T20:24:29","slug":"network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia","status":"publish","type":"post","link":"https:\/\/longchangextracts.com\/tr\/beni\u0307gn-prostat-hi\u0307perplazi\u0307si\u0307ni\u0307n-tedavi\u0307si\u0307nde-modi\u0307fi\u0307ye-gui\u0307zhi\u0307-fuli\u0307ng-hapinin-ag-farmakoloji\u0307si\u0307-ve-deneysel-calismasi\/","title":{"rendered":"\u0130yi huylu prostat hiperplazisinin tedavisinde modifiye Guizhi Fuling Hap\u0131n\u0131n a\u011f farmakolojisi ve deneysel \u00e7al\u0131\u015fmas\u0131"},"content":{"rendered":"<p>\u0130yi huylu prostat hiperplazisinin tedavisinde modifiye Guizhi Fuling Hap\u0131n\u0131n a\u011f farmakolojisi ve deneysel \u00e7al\u0131\u015fmas\u0131<br \/>\nBenign prostat hiperplazisi (BPH), iyi huylu prostat b\u00fcy\u00fcmesi (BPH) olarak adland\u0131r\u0131l\u0131r. Klinik insidans grubu \u00e7o\u011funlukla orta ya\u015fl\u0131 ve ya\u015fl\u0131 erkeklerdir. \u0130statistiklere g\u00f6re BPH'nin g\u00f6r\u00fclme oran\u0131 ya\u015fla birlikte artarak 80 ya\u015f\u0131nda 80%'ye ula\u015fmaktad\u0131r ve veriler y\u0131ldan y\u0131la artmaya devam etmektedir. BPH i\u00e7in tedavi y\u00f6ntemleri Bat\u0131 t\u0131bb\u0131 ve cerrahi tedaviyi i\u00e7erir, ancak Bat\u0131 t\u0131bb\u0131 tedavisi n\u00f6robili\u015f ve cinsel i\u015flevde hasara neden olabilirken, cerrahi tedaviye ameliyat sonras\u0131 komplikasyonlar e\u015flik eder. Bu nedenle, BPH i\u00e7in yeni tedavi yakla\u015f\u0131mlar\u0131n\u0131n ara\u015ft\u0131r\u0131lmas\u0131 acildir.<\/p>\n<p>Geleneksel \u00c7in t\u0131bb\u0131, hastal\u0131k tedavisinde zengin deneyime ve benzersiz avantajlara sahip b\u00fct\u00fcnsel bir yakla\u015f\u0131m\u0131 ve diyalektik tedaviyi vurgular. Guizhi Fuling Hap\u0131, Han Hanedanl\u0131\u011f\u0131 d\u00f6neminde ya\u015fam\u0131\u015f bir t\u0131p azizi olan Zhang Zhongjing'e aittir. Bu \u00e7al\u0131\u015fmada, modifiye edilmi\u015f Guizhi Fuling Hap\u0131 (MGFP) sekiz geleneksel \u00c7in ilac\u0131ndan olu\u015fturulmu\u015ftur: Guizhi, Fuling, Taoren, Mudan Skin, Chishao, Wangbuliuxing, Wuyao ve Leech. Ara\u015ft\u0131rma ekibi taraf\u0131ndan, \u00c7in t\u0131bb\u0131 ustas\u0131 Akademisyen Wang Qi taraf\u0131ndan BPH tedavisi i\u00e7in veri madencili\u011fine dayal\u0131 olarak \u00e7\u0131kar\u0131lan \u00e7ekirdek form\u00fcld\u00fc. Geleneksel \u00c7in t\u0131bb\u0131 teorisine g\u00f6re, BPH'nin patogenezi \"b\u00f6brek qi eksikli\u011fi ve kan staz t\u0131kan\u0131kl\u0131\u011f\u0131 \"d\u0131r. MGFP kan staz\u0131n\u0131 da\u011f\u0131tmada, semptomlar\u0131 ve birikimi azaltmada ve su dola\u015f\u0131m\u0131n\u0131 te\u015fvik etmede iyidir ve klinik kullan\u0131mda \u00f6nemli terap\u00f6tik etkilere sahiptir. Bununla birlikte, geleneksel \u00c7in t\u0131bb\u0131 form\u00fcllerinin karma\u015f\u0131k bile\u015fimi, etki mekanizmas\u0131n\u0131n incelenmesini b\u00fcy\u00fck \u00f6l\u00e7\u00fcde engellemektedir.<br \/>\nSon y\u0131llarda, a\u011f farmakolojisi geleneksel \u00c7in t\u0131bb\u0131 farmakolojisi \u00e7al\u0131\u015fmalar\u0131nda yayg\u0131n olarak kullan\u0131lmaktad\u0131r. Bu kavram, geleneksel \u00c7in t\u0131bb\u0131n\u0131n \u00e7ok bile\u015fenli, \u00e7ok hedefli ve \u00e7ok yollu teorisiyle \u00f6rt\u00fc\u015fen, birbirine ba\u011fl\u0131 a\u011fdaki birden fazla molek\u00fcl\u00fc hedefleyerek hastal\u0131klar\u0131n etkili ila\u00e7 tedavisi etraf\u0131nda d\u00f6nmektedir. Buna dayanarak, bu \u00e7al\u0131\u015fma MGFP'nin BPH \u00fczerindeki potansiyel etki mekanizmas\u0131n\u0131 ara\u015ft\u0131rmak i\u00e7in a\u011f farmakolojisi ve molek\u00fcler yerle\u015ftirme tekniklerini kullanmakta ve klinik tedaviye veri deste\u011fi sa\u011flamak amac\u0131yla en iyi ba\u011flanma enerjisine sahip hedefi do\u011frulamak i\u00e7in bir BPH model s\u0131\u00e7an\u0131 olu\u015fturmaktad\u0131r.<\/p>\n<p>&nbsp;<\/p>\n<p>Raporlara g\u00f6re, BPH'nin patogenezi esas olarak seks hormonlar\u0131, b\u00fcy\u00fcme fakt\u00f6rleri, inflamatuar yan\u0131t, anormal h\u00fccre apoptozu vb. ile ilgilidir. Ana patolojik \u00f6zellikleri prostat epitel h\u00fccrelerinin ve stromal h\u00fccrelerin \u00e7o\u011falmas\u0131d\u0131r. MGFP, so\u011fuk ve s\u0131cak ile birlikte kullan\u0131ld\u0131\u011f\u0131nda, kan dola\u015f\u0131m\u0131n\u0131 te\u015fvik etme, semptomlar\u0131 ortadan kald\u0131rma, yumu\u015fatma, g\u00fc\u00e7lendirme ve di\u00fcrezi te\u015fvik etme etkilerine sahiptir. B\u00f6brek qi eksikli\u011fi ve kan staz t\u0131kan\u0131kl\u0131\u011f\u0131n\u0131n neden oldu\u011fu BPH'yi \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015ftirebilir. Modern farmakolojik ara\u015ft\u0131rmalar, Guizhi Fuling Pill'in bile\u015fenlerinin esas olarak paeonol, paeoniflorin, sinnamaldehit, porin ve amigdalin i\u00e7erdi\u011fini g\u00f6stermi\u015ftir. Hemoreolojik parametreleri iyile\u015ftirerek kan viskozitesini azaltabilir ve genellikle kan staz\u0131 (bulan\u0131kl\u0131k) birikiminin neden oldu\u011fu BPH gibi hastal\u0131klar\u0131 tedavi etmek i\u00e7in kullan\u0131l\u0131r. Ayr\u0131ca Wang Buliuxing'in kan staz\u0131 modeli s\u0131\u00e7anlar\u0131n p\u0131ht\u0131la\u015fma s\u00fcresini uzatabildi\u011fi ve tam kan viskozitesini azaltabildi\u011fi; s\u00fcl\u00fcklerde bulunan hirudinin anti p\u0131ht\u0131la\u015fma ve anti trombotik etkilere sahip oldu\u011fu; kara ilac\u0131n ana bile\u015feni olan u\u00e7ucu ya\u011f\u0131n da akci\u011fer qi'sini serbest b\u0131rakabildi\u011fi ve idrar ta\u015flar\u0131n\u0131n tutulmas\u0131n\u0131 hafifletmek i\u00e7in mesaneyi indirebildi\u011fi, b\u00f6ylece idrara \u00e7\u0131kmay\u0131 kolayla\u015ft\u0131rd\u0131\u011f\u0131 bulunmu\u015ftur. Buradan, MGFP'deki kimyasal bile\u015fenlerin, birden fazla bile\u015fen, hedef ve yola sahip geleneksel \u00c7in t\u0131bb\u0131 bile\u015fi\u011finin etki mekanizmas\u0131n\u0131 yans\u0131tan belirli yollar arac\u0131l\u0131\u011f\u0131yla BPH'yi tedavi etme hedefine ula\u015fabilece\u011fi g\u00f6r\u00fclebilir.<br \/>\nBu \u00e7al\u0131\u015fma, Venn diyagram\u0131 arac\u0131l\u0131\u011f\u0131yla 212 kesi\u015fen hedef elde etmi\u015f ve ard\u0131ndan BPH'nin MGFP tedavisi i\u00e7in \u00e7ekirdek hedefleri belirlemek \u00fczere KOBAS analizindeki \u00e7ekirdek yolaklar\u0131 ters e\u015fle\u015ftirmi\u015ftir. Derece s\u0131ralamas\u0131 ve literat\u00fcrle birlikte, AKT1 BAX\u3001BCL2\u3001JUN\u3001TGFB1\u3001TNF\u3001IL6\u3001VEGFA\u3001EGFR dahil olmak \u00fczere BPH patogeneziyle yak\u0131ndan ili\u015fkili \u00e7ekirdek hedefler elde edilmi\u015ftir\u3002 Yukar\u0131daki hedefler esas olarak h\u00fccre apoptozu, vask\u00fcler b\u00fcy\u00fcme ve inflamasyonla ilgilidir. Raporlara g\u00f6re, AKT bir serin\/treonin protein kinazd\u0131r. AKT alt tipinde, AKT1 apoptozu inhibe edebilir ve BPH geli\u015fimine kat\u0131larak h\u00fccre b\u00fcy\u00fcmesini ve hayatta kalmas\u0131n\u0131 te\u015fvik edebilir. VEGFA, prostat neovask\u00fclarizasyonunun olu\u015fumu ve s\u00fcrd\u00fcr\u00fclmesi ile yak\u0131ndan ili\u015fkili olduk\u00e7a spesifik bir vask\u00fcler endotelyal h\u00fccre mitojenidir. Aktive AKT, NO \u00fcretmek i\u00e7in eNOS'u fosforile ederek VEGFA kaynakl\u0131 endotel h\u00fccre g\u00f6\u00e7\u00fcn\u00fc, vazodilatasyonu, kan ak\u0131\u015f\u0131n\u0131n artmas\u0131n\u0131 ve anjiyogenezi te\u015fvik eder. IL-6 \u00e7ok \u00e7e\u015fitli i\u015flevlere sahip \u00e7ok fonksiyonlu bir sitokindir. Prostat dokusunda IL-6, otokrin yolak arac\u0131l\u0131\u011f\u0131yla prostat bazal epitel h\u00fccrelerinin \u00e7o\u011falmas\u0131n\u0131 te\u015fvik ederek v\u00fccutta prostat h\u00fccre \u00e7o\u011falmas\u0131 ve apoptoz aras\u0131nda bir dengesizli\u011fe neden olur ve b\u00f6ylece BPH olu\u015fumunu tetikler.<br \/>\nBu \u00e7al\u0131\u015fma, GO fonksiyonel ek a\u00e7\u0131klama analizi yoluyla MGFP'de yer alan biyolojik s\u00fcre\u00e7lerin esas olarak vask\u00fcler b\u00fcy\u00fcme ile ilgili s\u00fcre\u00e7ler, oksidatif stres ile ilgili s\u00fcre\u00e7ler, apoptoz ile ilgili s\u00fcre\u00e7ler, p\u0131ht\u0131la\u015fma ile ilgili s\u00fcre\u00e7ler ve ba\u011f\u0131\u015f\u0131kl\u0131k ile ilgili s\u00fcre\u00e7lerde zenginle\u015ftirildi\u011fini bulmu\u015ftur. BPH'nin d\u00fczenlenmesindeki molek\u00fcler i\u015flevleri temel olarak transkripsiyon fakt\u00f6r\u00fc ba\u011flanmas\u0131, n\u00fckleer resept\u00f6r aktivitesi, protein kinaz aktivitesi, sitokin resept\u00f6r\u00fc ba\u011flanmas\u0131, adrenerjik resept\u00f6r aktivitesi, RNA polimeraz II transkripsiyon fakt\u00f6r\u00fc ba\u011flanmas\u0131 vb. alanlarda zenginle\u015fmi\u015ftir.<br \/>\nBu \u00e7al\u0131\u015fma, KEGG yol zenginle\u015ftirme analizi yoluyla MGFP'nin AGE-RAGE sinyal yolu, PI3K-AKT sinyal yolu, h\u00fccre apoptozu, IL-17 sinyal yolu, Th17 h\u00fccre farkl\u0131la\u015fmas\u0131, TNF sinyal yolu, VEGF sinyal yolu, MAPK sinyal yolu, Ras sinyal yolu, Rap1 sinyal yolu vb. \u00fczerinde d\u00fczenleyici etkileri oldu\u011funu bulmu\u015ftur. Ara\u015ft\u0131rmalar, AGERAGE'in pro-enflamatuar sitokinlerin \u00fcretimini uyararak a\u015f\u0131r\u0131 h\u00fccre \u00e7o\u011falmas\u0131na ve BPH'nin daha da geli\u015fmesine yol a\u00e7abilece\u011fini g\u00f6stermi\u015ftir. PI3K-AKT sinyal yolunun aktivasyonu pro apoptotik proteinlerin fosforilasyonuna yol a\u00e7ar, bu da anti apoptotik molek\u00fcller BCL-2 ve BCL-XL'ye ba\u011flanmalar\u0131n\u0131 engelleyerek BPH'de h\u00fccre apoptozunun azalmas\u0131na neden olur. IL-17 sinyal yolu, Th17 h\u00fccre farkl\u0131la\u015fmas\u0131 ve TNF sinyal yolunun t\u00fcm\u00fc imm\u00fcn inflamatuar yan\u0131tlara arac\u0131l\u0131k edebilir. Enfeksiyon uyar\u0131m\u0131n\u0131n BPH stromal h\u00fccrelerinin pro-enflamatuar fakt\u00f6rler IL-6, IL-8 ve TNF \u00fcretmesine neden oldu\u011fu, b\u00f6ylece infiltrasyon yapan CD4+T h\u00fccrelerini aktive etti\u011fi ve IL12 ve IL-23 salg\u0131layarak Th1 ve Th17 efekt\u00f6r h\u00fccrelerinde farkl\u0131la\u015fmalar\u0131n\u0131 te\u015fvik etti\u011fi bildirilmi\u015ftir; Aktive Th1 ve Th17 lenfositleri, imm\u00fcn enflamatuar yan\u0131tlar\u0131 te\u015fvik eden ve prostat h\u00fccresi hiperplazisine yol a\u00e7an IL-17 gibi pro-enflamatuar sitokinler \u00fcretir. VEGF, interstisyel dokularda anjiyogenezi ve h\u00fccre proliferasyonunu te\u015fvik edebilen PI3K-AKT sinyal yolunun arac\u0131l\u0131k etti\u011fi anjiyojenik bir fakt\u00f6rd\u00fcr. Ayr\u0131ca BPH geli\u015fiminde de \u00f6nemli bir rol oynar. \u00c7ekirdek hedefin sonu\u00e7lar\u0131 ve \u015eekil 6 ile birlikte, PI3K-AKT sinyal yola\u011f\u0131 ile VEGF sinyal yola\u011f\u0131 aras\u0131nda yak\u0131n bir ili\u015fki oldu\u011funu tahmin ediyoruz. MAPK ve Ras sinyal yolaklar\u0131, proliferasyon, apoptoz, farkl\u0131la\u015fma ve ya\u015flanma dahil olmak \u00fczere h\u00fccrelerin temel biyolojik faaliyetlerinin d\u00fczenlenmesinde rol oynar. MAPK kaskad\u0131 Ras'a ba\u011f\u0131ml\u0131d\u0131r ve anormal aktivasyon v\u00fccutta h\u00fccre \u00e7o\u011falmas\u0131 ve apoptoz aras\u0131nda bir dengesizli\u011fe neden olabilir. Buna ek olarak, Rap1 sinyal yolunun aktivasyonunun h\u00fccre \u00e7o\u011falmas\u0131n\u0131 ve g\u00f6\u00e7\u00fcn\u00fc te\u015fvik ederek prostat hacminde art\u0131\u015fa yol a\u00e7t\u0131\u011f\u0131 bulunmu\u015ftur. MGFP'nin \u00e7oklu sinyal yollar\u0131n\u0131 d\u00fczenleyerek enflamatuar yan\u0131t\u0131, h\u00fccre apoptozunu ve proliferasyonunu etkileyebilece\u011fi ve b\u00f6ylece BPH tedavisi hedefine ula\u015fabilece\u011fi tahmin edilmektedir.<br \/>\nBu \u00e7al\u0131\u015fma, molek\u00fcler yerle\u015ftirme yoluyla MGFP'nin kuersetin, \u03b2 - sitosterol, kaempferol, baicalein ve tannik asit gibi \u00e7ekirdek bile\u015fenlerinin AKT1, BAX, BCL2, JUN, TGFB1, TNF, IL6, VEGFA ve EGFR ile 0'dan d\u00fc\u015f\u00fck ba\u011flanma enerjilerine sahip oldu\u011funu ve bunlar\u0131n kendili\u011finden birbirlerine ba\u011flanabilece\u011fini g\u00f6stermi\u015ftir. Bununla birlikte, quercetin, \u03b2 - sitosterol, kaempferol, baicalein ve tannik asidin AKT1, BAX, JUN, TNF ve VEGFA ile ba\u011flanma enerjilerinin t\u00fcm\u00fc -20929 J\/mol'den d\u00fc\u015f\u00fckt\u00fcr ve bu da g\u00fc\u00e7l\u00fc ba\u011flanma kabiliyetini g\u00f6sterir. BAX ve \u03b2 - sitosterol aras\u0131ndaki kenetlenme sonucu en iyisidir. Ara\u015ft\u0131rmalar, \u03b2 - sitosterol\u00fcn \u00e7e\u015fitli h\u00fccresel sinyal yollar\u0131na m\u00fcdahale eden, h\u00fccre d\u00f6ng\u00fcs\u00fc, apoptoz, proliferasyon ve anjiyogenez gibi s\u00fcre\u00e7leri etkileyen bir bitki sterol\u00fc oldu\u011funu g\u00f6stermi\u015ftir. Kalp hastal\u0131\u011f\u0131, t\u00fcberk\u00fcloz ve rahim a\u011fz\u0131 kanseri gibi hastal\u0131klarda klinik olarak yayg\u0131n \u015fekilde kullan\u0131l\u0131r. H\u00fccre apoptozu s\u00fcrecinde, pro apoptotik BAX mitokondriye translokasyon yapar ve mitokondrinin d\u0131\u015f membran\u0131 ile b\u00fct\u00fcnle\u015ferek d\u0131\u015f membran permeabilizasyonunu ind\u00fckler ve sitokrom c'yi serbest b\u0131rakarak normal h\u00fccre \u00f6l\u00fcm\u00fcne yol a\u00e7ar. Sharmila ve arkada\u015flar\u0131 dietilnitrozamin ile ind\u00fcklenen bir s\u0131\u00e7an b\u00f6brek kanseri modeli olu\u015fturmu\u015f ve BAX proteini ekspresyonunun \u03b2 - sitosterol tedavi grubunda \u00f6nemli \u00f6l\u00e7\u00fcde artt\u0131\u011f\u0131n\u0131 bulmu\u015flard\u0131r. Buna ek olarak, \u00e7ok merkezli, plasebo kontroll\u00fc, \u00e7ift k\u00f6r bir \u00e7al\u0131\u015fma, \u03b2 - sitosterol\u00fcn BPH \u00fczerinde de \u00f6nemli bir iyile\u015ftirme etkisine sahip oldu\u011funu g\u00f6stermi\u015ftir, ancak etki mekanizmas\u0131 hala belirsizdir.<br \/>\nBu \u00e7al\u0131\u015fmada, bir BPH s\u0131\u00e7an modeli olu\u015fturularak prostat dokusunda BAX ekspresyonu ara\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r. Sonu\u00e7lar, sham cerrahi grubu ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, model grubu s\u0131\u00e7anlarda gland\u00fcler epitel h\u00fccre proliferasyonu ve \u00f6nemli \u00f6l\u00e7\u00fcde azalm\u0131\u015f gland\u00fcler l\u00fcmen oldu\u011funu g\u00f6sterirken, di\u011fer tedavi gruplar\u0131 model grubu ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda prostat duvar kal\u0131nl\u0131\u011f\u0131nda de\u011fi\u015fen derecelerde azalma g\u00f6stermi\u015ftir, bu da MGFP'nin BPH modeli s\u0131\u00e7anlar \u00fczerinde belirli bir terap\u00f6tik etkiye sahip oldu\u011funu d\u00fc\u015f\u00fcnd\u00fcrmektedir. \u0130mm\u00fcnohistokimyan\u0131n yar\u0131 kantitatif sonu\u00e7lar\u0131, prostat dokusunda BAX ekspresyonunda bo\u015f grup ile sham cerrahi grubu aras\u0131nda anlaml\u0131 bir fark olmad\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir; sham cerrahi grubu ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, model grubu s\u0131\u00e7anlar\u0131n prostat dokusunda BAX ekspresyonu \u00f6nemli \u00f6l\u00e7\u00fcde azalm\u0131\u015ft\u0131r (P&lt;0.01), bu da BPH&#039;nin prostat dokusunda BAX ekspresyonunu inhibe ederek anormal h\u00fccre apoptozuna neden olabilece\u011fini g\u00f6stermektedir. Model grupla kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, MGFP&#039;nin d\u00fc\u015f\u00fck, orta ve y\u00fcksek doz gruplar\u0131, finasterid grubu ve Longbishu kaps\u00fcl grubunun t\u00fcm\u00fc BAX ekspresyonunu \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131rm\u0131\u015ft\u0131r (P&lt;0.01), bu da h\u00fccre apoptozunu te\u015fvik etmekle ilgili BAX geninin ekspresyonunu art\u0131ran, h\u00fccre \u00e7o\u011falmas\u0131n\u0131 engelleyen ve doza ba\u011fl\u0131 bir etkiye sahip olan MGFP taraf\u0131ndan mitokondriyal ba\u011f\u0131ml\u0131 apoptoz yolunun d\u00fczenlenmesinden kaynaklan\u0131yor olabilir.<br \/>\n\u00d6zetle, MGFP AKT1, BAX, JUN, TNF, VEGFA gibi hedeflerin yan\u0131 s\u0131ra kuersetin, \u03b2 - sitosterol, kaempferol, baicalein ve tannik asit gibi \u00e7ekirdek bile\u015fenler arac\u0131l\u0131\u011f\u0131yla PI3K-AKT ve VEGF sinyal yolaklar\u0131n\u0131 d\u00fczenleyebilir, b\u00f6ylece prostat vask\u00fcler b\u00fcy\u00fcmesi, apoptoz ve oksidatif stres gibi ilgili biyolojik s\u00fcre\u00e7leri d\u00fczenleyebilir ve BPH \u00fczerinde terap\u00f6tik bir etki g\u00f6sterebilir. \u00c7ekirdek bile\u015fen ve temel hedefler aras\u0131ndaki optimum ba\u011flanma modunun molek\u00fcler yerle\u015ftirme ile \u00f6n tahmini \u03b2 - sitosterol BAX idi ve MGFP'nin BAX \u00fczerindeki etkisi hayvan deneyleri yoluyla ara\u015ft\u0131r\u0131larak MGFP'nin yayg\u0131n uygulamas\u0131 i\u00e7in farmakolojik bir temel sa\u011fland\u0131. Kimyasal bile\u015fenlerin veri taban\u0131na yeterince dahil edilmemesi ve geleneksel \u00c7in t\u0131bb\u0131 bile\u015fenlerinin i\u015flendikten sonra de\u011fi\u015fmesi gibi s\u0131n\u0131rlamalar g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, MGFP'nin kimyasal bile\u015fenleri \u00fczerinde parmak izi teknolojisi arac\u0131l\u0131\u011f\u0131yla daha derinlemesine ara\u015ft\u0131rmalar yap\u0131labilir ve bu da a\u011f farmakolojisi tahmin sonu\u00e7lar\u0131n\u0131n g\u00fcvenilirli\u011fini art\u0131rmaya yard\u0131mc\u0131 olacakt\u0131r.<\/p>","protected":false},"excerpt":{"rendered":"<p>Network pharmacology and experimental study of modified Guizhi Fuling Pill in the treatment of benign prostatic hyperplasia Benign prostatic hyperplasia (BPH) is referred to as benign prostatic hyperplasia (BPH). The clinical incidence group is mostly middle-aged and elderly men. According to statistics, the incidence rate of BPH increases with age, reaching 80% at the age [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Network pharmacology and experimental study of modified Guizhi Fuling Pill in the treatment of benign prostatic hyperplasia - China Chemical Manufacturer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/longchangextracts.com\/tr\/beni\u0307gn-prostat-hi\u0307perplazi\u0307si\u0307ni\u0307n-tedavi\u0307si\u0307nde-modi\u0307fi\u0307ye-gui\u0307zhi\u0307-fuli\u0307ng-hapinin-ag-farmakoloji\u0307si\u0307-ve-deneysel-calismasi\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Network pharmacology and experimental study of modified Guizhi Fuling Pill in the treatment of benign prostatic hyperplasia - China Chemical Manufacturer\" \/>\n<meta property=\"og:description\" content=\"Network pharmacology and experimental study of modified Guizhi Fuling Pill in the treatment of benign prostatic hyperplasia Benign prostatic hyperplasia (BPH) is referred to as benign prostatic hyperplasia (BPH). The clinical incidence group is mostly middle-aged and elderly men. According to statistics, the incidence rate of BPH increases with age, reaching 80% at the age [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/longchangextracts.com\/tr\/beni\u0307gn-prostat-hi\u0307perplazi\u0307si\u0307ni\u0307n-tedavi\u0307si\u0307nde-modi\u0307fi\u0307ye-gui\u0307zhi\u0307-fuli\u0307ng-hapinin-ag-farmakoloji\u0307si\u0307-ve-deneysel-calismasi\/\" \/>\n<meta property=\"og:site_name\" content=\"China Chemical Manufacturer\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-11T20:24:29+00:00\" \/>\n<meta name=\"author\" content=\"longcha9\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"longcha9\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/longchangextracts.com\/network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia\/\",\"url\":\"https:\/\/longchangextracts.com\/network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia\/\",\"name\":\"Network pharmacology and experimental study of modified Guizhi Fuling Pill in the treatment of benign prostatic hyperplasia - China Chemical Manufacturer\",\"isPartOf\":{\"@id\":\"https:\/\/longchangextracts.com\/#website\"},\"datePublished\":\"2024-08-11T20:24:29+00:00\",\"dateModified\":\"2024-08-11T20:24:29+00:00\",\"author\":{\"@id\":\"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869\"},\"breadcrumb\":{\"@id\":\"https:\/\/longchangextracts.com\/network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/longchangextracts.com\/network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/longchangextracts.com\/network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/longchangextracts.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Network pharmacology and experimental study of modified Guizhi Fuling Pill in the treatment of benign prostatic hyperplasia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/longchangextracts.com\/#website\",\"url\":\"https:\/\/longchangextracts.com\/\",\"name\":\"China Chemical Manufacturer\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/longchangextracts.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869\",\"name\":\"longcha9\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/longchangextracts.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g\",\"caption\":\"longcha9\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0130yi huylu prostat hiperplazisinin tedavisinde modifiye Guizhi Fuling Hap\u0131n\u0131n a\u011f farmakolojisi ve deneysel \u00e7al\u0131\u015fmas\u0131 - \u00c7in Kimya \u00dcreticisi","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/longchangextracts.com\/tr\/beni\u0307gn-prostat-hi\u0307perplazi\u0307si\u0307ni\u0307n-tedavi\u0307si\u0307nde-modi\u0307fi\u0307ye-gui\u0307zhi\u0307-fuli\u0307ng-hapinin-ag-farmakoloji\u0307si\u0307-ve-deneysel-calismasi\/","og_locale":"tr_TR","og_type":"article","og_title":"Network pharmacology and experimental study of modified Guizhi Fuling Pill in the treatment of benign prostatic hyperplasia - China Chemical Manufacturer","og_description":"Network pharmacology and experimental study of modified Guizhi Fuling Pill in the treatment of benign prostatic hyperplasia Benign prostatic hyperplasia (BPH) is referred to as benign prostatic hyperplasia (BPH). The clinical incidence group is mostly middle-aged and elderly men. According to statistics, the incidence rate of BPH increases with age, reaching 80% at the age [&hellip;]","og_url":"https:\/\/longchangextracts.com\/tr\/beni\u0307gn-prostat-hi\u0307perplazi\u0307si\u0307ni\u0307n-tedavi\u0307si\u0307nde-modi\u0307fi\u0307ye-gui\u0307zhi\u0307-fuli\u0307ng-hapinin-ag-farmakoloji\u0307si\u0307-ve-deneysel-calismasi\/","og_site_name":"China Chemical Manufacturer","article_published_time":"2024-08-11T20:24:29+00:00","author":"longcha9","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"longcha9","Tahmini okuma s\u00fcresi":"8 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/longchangextracts.com\/network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia\/","url":"https:\/\/longchangextracts.com\/network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia\/","name":"\u0130yi huylu prostat hiperplazisinin tedavisinde modifiye Guizhi Fuling Hap\u0131n\u0131n a\u011f farmakolojisi ve deneysel \u00e7al\u0131\u015fmas\u0131 - \u00c7in Kimya \u00dcreticisi","isPartOf":{"@id":"https:\/\/longchangextracts.com\/#website"},"datePublished":"2024-08-11T20:24:29+00:00","dateModified":"2024-08-11T20:24:29+00:00","author":{"@id":"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869"},"breadcrumb":{"@id":"https:\/\/longchangextracts.com\/network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/longchangextracts.com\/network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/longchangextracts.com\/network-pharmacology-and-experimental-study-of-modified-guizhi-fuling-pill-in-the-treatment-of-benign-prostatic-hyperplasia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/longchangextracts.com\/"},{"@type":"ListItem","position":2,"name":"Network pharmacology and experimental study of modified Guizhi Fuling Pill in the treatment of benign prostatic hyperplasia"}]},{"@type":"WebSite","@id":"https:\/\/longchangextracts.com\/#website","url":"https:\/\/longchangextracts.com\/","name":"\u00c7in Kimyasal \u00dcreticisi","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/longchangextracts.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869","name":"longcha9","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/longchangextracts.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g","caption":"longcha9"}}]}},"_links":{"self":[{"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/posts\/8223"}],"collection":[{"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/comments?post=8223"}],"version-history":[{"count":1,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/posts\/8223\/revisions"}],"predecessor-version":[{"id":8224,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/posts\/8223\/revisions\/8224"}],"wp:attachment":[{"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/media?parent=8223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/categories?post=8223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/tags?post=8223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}